The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Amyloid β-peptide (1-42)-induced Oxidative Stress and Neurotoxicity: Implications for Neurodegeneration in Alzheimer's Disease Brain. A Review
Abstract
Oxidative stress, manifested by protein oxidation, lipid peroxidation, DNA oxidation and 3-nitrotyrosine formation, among other indices, is observed in Alzheimer's disease (AD) brain. Amyloid beta-peptide (1-42) [Abeta(1-42)] may be central to the pathogenesis of AD. Our laboratory and others have implicated Abeta(1-42)-induced free radical oxidative stress in the neurodegeneration observed in AD brain. This paper reviews some of these studies from our laboratory. Recently, we showed both in-vitro and in-vivo that methionine residue 35 (Met-35) of Abeta(1-42) was critical to its oxidative stress and neurotoxic properties. Because the C-terminal region of Abeta(1-42) is helical, and invoking the i + 4 rule of helices, we hypothesized that the carboxyl oxygen of lle-31, known to be within a van der Waals distance of the S atom of Met-35, would interact with the latter. This interaction could alter the susceptibility for oxidation of Met-35, i.e. free radical formation. Consistent with this hypothesis, substitution of lle-31 by the helix-breaking amino acid, proline, completely abrogated the oxidative stress and neurotoxic properties of Abeta(1-42). Removal of the Met-35 residue from the lipid bilayer by substitution of the negatively charged Asp for Gly-37 abrogated oxidative stress and neurotoxic properties of Abeta(1-42). The free radical scavenger vitamin E prevented A(beta (1-42)-induced ROS formation, protein oxidation, lipid peroxidation, and neurotoxicity in hippocampal neurons, consistent with our model for Abeta-associated free radical oxidative stress induced neurodegeneration in AD. ApoE, allele 4, is a risk factor for AD. Synaptosomes from apoE knock-out mice are more vulnerable to Abeta-induced oxidative stress (protein oxidation, lipid peroxidation, and ROS generation) than are those from wild-type mice. We also studied synaptosomes from allele-specific human apoE knock-in mice. Brain membranes from human apoE4 mice have greater vulnerability to Abeta(1-42)-induced oxidative stress than brain membranes from apoE2 or E3, assessed by the same indices, consistent with the notion of a coupling of the oxidative environment in AD brain and increased risk of developing this disorder. Using immunoprecipitation of proteins from AD and control brain obtained no longer than 4h PMI, selective oxidized proteins were identified in the AD brain. Creatine kinase (CK) and beta-actin have increased carbonyl groups, an index of protein oxidation, and Glt-1, the principal glutamate transporter, has increased binding of the lipid peroxidation product, 4-hydroxy-2-nonenal (HNE). Abeta inhibits CK and causes lipid peroxidation, leading to HNE formation. Implications of these findings relate to decreased energy utilization, altered assembly of cytoskeletal proteins, and increased excitotoxicity to neurons by glutamate, all reported for AD. Other oxidatively modified proteins have been identified in AD brain by proteomics analysis, and these oxidatively-modified proteins may be related to increased excitotoxicity (glutamine synthetase), aberrant proteasomal degradation of damaged or aggregated proteins (ubiquitin C-terminal hydrolase L-1), altered energy production (alpha-enolase), and diminished growth cone elongation and directionality (dihydropyrimindase-related protein 2). Taken together, these studies outlined above suggest that Met-35 is key to the oxidative stress and neurotoxic properties of Abeta(1-42) and may help explain the apoE allele dependence on risk for AD, some of the functional and structural alterations in AD brain, and strongly support a causative role of Abeta(1-42)-induced oxidative stress and neurodegeneration in AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxidative stress and mitochondrial dysfunction are prominent features of many neurodegenerative diseases including AD (Butterfield, 2002; Butterfield and Boyd-Kimball, 2018; Sharma and Kim, 2021).”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Butterfield, 2002
In the citing paper
“For the same reason, the Aβ insertion into the lipid bilayer of the neuronal plasma membrane induces lipid peroxidation in a direct manner (Butterfield, 2002).”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Butterfield, 2002
Citations
Cites
Free radicals in biology and medicine
Gutteridge, J. M. C. (1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90478-o · Cited by 17,178
Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
Esterbauer, H., Schaur, R. J., & Zollner, H. (1991) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(91)90192-6 · Cited by 6,672
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Oxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296
Amyloid β-Protein Fibrillogenesis
Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., & Teplow, D. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25945 · Cited by 1,046
Butterfield, D. A., & Lauderback, C. M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00794-3 · Cited by 1,013
Impaired Proteasome Function in Alzheimer's Disease
Keller, J. N., Hanni, K. B., & Markesbery, W. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750436.x · Cited by 848
Mark, R. J., Lovell, M. A., Markesbery, W. R., Uchida, K., & Mattson, M. P. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010255.x · Cited by 781
Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, S. P., Wu, J. F., Carney, J. M., et al. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65052146.x · Cited by 779 · cited 17×
“One could speculate that decreased information (memory) processing could result, which, of course, is a hallmark of AD.”
InfluentialReview: Alzheimer's Amyloid β-Peptide-Associated Free Radical Oxidative Stress and Neurotoxicity
Varadarajan, S., Yatin, S., Aksenova, M., & Butterfield, D. A. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4274 · Cited by 735
Allanbutterfield, D., Castegna, A., Lauderback, C. M., & Drake, J. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00340-2 · Cited by 715
Self-citationMarkesbery, W. R., & Lovell, M. A. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00009-8 · Cited by 680
Curtain, C. C., Ali, F. E. A., Volitakis, I., Cherny, R. A., Norton, R. S., Beyreuther, K. T., Barrow, C. J., Masters, C. L., Bush, A. I., & Barnham, K. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100175200 · Cited by 658
Castegna, A., Aksenov, M. Y., Thongboonkerd, V., Klein, J. B., Pierce, W. M. J., Booze, R. M., Markesbery, W. R., & Butterfield, D. A. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01103.x · Cited by 581
Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R., Markesbery, W. R., & Butterfield, D. A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00914-0 · Cited by 581
Mark, R. J., Hensley, K., Butterfield, D. A., & Mattson, M. P. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-09-06239.1995 · Cited by 553
Mark, R. J., Pang, Z., Geddes, J. W., Uchida, K., & Mattson, M. P. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-03-01046.1997 · Cited by 551
Clearing the brain's amyloid cobwebs
Selkoe, D. J. (2001) · Neuron · doi:10.1016/s0896-6273(01)00475-5 · Cited by 541
Coles, M. P., Bicknell, W., Watson, A. A., Fairlie, D. P., & Craik, D. J. (1998) · Biochemistry · doi:10.1021/bi972979f · Cited by 526
Protein oxidation in the brain in Alzheimer's disease
Aksenov, M. Y., Aksenova, M. V., Butterfield, D. A., Geddes, J. W., & Markesbery, W. R. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00580-7 · Cited by 505
Deficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease
Masliah, E., Hansen, L., Alford, M., Deteresa, R., & Mallory, M. (1996) · Annals of Neurology · doi:10.1002/ana.410400512 · Cited by 476
Acrolein is increased in Alzheimer’s disease brain and is toxic to primary hippocampal cultures
Lovell, M. A., Xie, C., & Markesbery, W. R. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00235-9 · Cited by 449
Butterfield, D. A., Hensley, K., Harris‐White, M. E., Mattson, M. P., & Carney, J. M. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1508 · Cited by 404
Chapter 7 Protein Oxidation Processes in Aging Brain
Butterfield, D. A., & Stadtman, E. R. (1997) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(08)60057-7 · Cited by 390
Butterfield, D. A. (1997) · Chemical Research in Toxicology · doi:10.1021/tx960130e · Cited by 364
Keller, J. N., Mark, R. J., Bruce‐Keller, A. J., Blanc, E. M., Rothstein, J. D., Uchida, K., Waeg, G., & Mattson, M. P. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00065-1 · Cited by 362
Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., et al. (1995) · Experimental Neurology · doi:10.1006/exnr.1995.1080 · Cited by 352
Different Mechanisms of Oxidative Stress and Neurotoxicity for Alzheimer‘s Aβ(1−42) and Aβ(25−35)
Varadarajan, S., Kanski, J., Aksenova, M., Lauderback, C., & Butterfield, D. A. (2001) · Journal of the American Chemical Society · doi:10.1021/ja010452r · Cited by 346
(1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00056-1 · Cited by 330
Self-citationShao, H., Jao, S., Ma, K., & Zagorski, M. G. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2348 · Cited by 308
Oxidative Modification of Creatine Kinase BB in Alzheimer’s Disease Brain
Aksenov, M. Y., Aksenova, M. V., Butterfield, D. A., & Markesbery, W. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742520.x · Cited by 286
The Glutamatergic System and Alzheimer???s Disease
Butterfield, D. A., & Pocernich, C. B. (2003) · CNS Drugs · doi:10.2165/00023210-200317090-00004 · Cited by 274
Subramaniam, R., Roediger, F., Jordan, B., Mattson, M. P., Keller, J. N., Waeg, G., & Butterfield, D. A. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031161.x · Cited by 270
Keller, J. (2002) · Ageing Research Reviews · doi:10.1016/s1568-1637(01)00006-x · Cited by 247
Protein turnover by the proteasome in aging and disease
Shringarpure, R., & Davies, K. J. A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00824-9 · Cited by 236
Butterfield, D. A., Hensley, K., Cole, P. S., Ramachandran, S., Aksenov, M. Y., Aksenova, M. V., Bummer, P. M., Haley, B. E., & Carney, J. M. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68062451.x · Cited by 191
Bruce‐Keller, A. J., Begley, J. G., Fu, W., Butterfield, D. A., Bredesen, D. E., Hutchins, J. B., Hensley, K., & Mattson, M. P. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70010031.x · Cited by 188
Pocernich, C. B., Cardin, A. L., Racine, C. L., Lauderback, C. M., & Butterfield, D. A. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00012-2 · Cited by 183
Evidence That Collapsin Response Mediator Protein-2 Is Involved in the Dynamics of Microtubules
Gu, Y., & Ihara, Y. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000179200 · Cited by 169
Blass, J. P. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.10087 · Cited by 165
Beffert, U., Cohn, J. S., Petit-Turcotte, C., Tremblay, M., Aumont, N., Ramassamy, C., Davignon, J., & Poirier, J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01894-6 · Cited by 142
Lauderback, C. M., Kański, J., Hackett, J. M., Maeda, N., Kindy, M. S., & Butterfield, D. A. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03228-0 · Cited by 134
Gridley, K. E., Green, P. S., & Simpkins, J. W. (1997) · Brain Research · doi:10.1016/s0006-8993(97)01056-1 · Cited by 131
Lee, M. K. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00633-5 · Cited by 112
Yatin, S. M., Aksenov, M. Y., & Butterfield, D. A. (1999) · Neurochemical Research · doi:10.1023/a:1020997903147 · Cited by 112
Avdulov, N. A., Chochina, S. V., Igbavboa, U., O‘Hare, E., Schroeder, F., Cleary, J. P., & Wood, W. G. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052086.x · Cited by 106
Yatin, S. M., Yatin, M., Aulick, T., Ain, K. B., & Butterfield, D. A. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00101-9 · Cited by 97
Kański, J., Aksenova, M. V., Schöneich, C., & Butterfield, D. A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00821-3 · Cited by 93
Melatonin prevents β‐amyloid‐induced lipid peroxidation
Daniels, W. M. U., van Rensburg, S. J., van Zyl, J. M., & Taljaard, J. J. F. (1998) · Journal of Pineal Research · doi:10.1111/j.1600-079x.1998.tb00370.x · Cited by 84
Oxidative Modification of Glutamine Synthetase by Amyloid Beta Peptide
Aksenov, M. Y., Aksenova, M. V., Carney, J. M., & Butterfield, D. A. (1997) · Free Radical Research · doi:10.3109/10715769709065765 · Cited by 81
ADDLs & protofibrils —the missing links?
Klein, W. L. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00312-8 · Cited by 77
Koppal, T., Subramaniam, R., Drake, J., Prasad, M. R., Dhillon, H. S., & Butterfield, D. A. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01466-2 · Cited by 77
Aksenov, M. Y., Aksenova, M. V., Butterfield, D. A., Hensley, K., Vigo‐Pelfrey, C., & Carney, J. M. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66052050.x · Cited by 59
Kański, J., Aksenova, M. V., & Butterfield, D. A. (2002) · Neurotoxicity Research · doi:10.1080/10298420290023945 · Cited by 58
Characterization of 8‐Epiprostaglandin F2α as aMarker of Amyloid β‐Peptide‐Induced Oxidative Damage
Mark, R. J., Fuson, K. S., & May, P. C. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721146.x · Cited by 46
Quantitative imaging of tyrosine hydroxylase and calmodulin in the human brain
Sutoo, D., Akiyama, K., & Yabe, K. (2001) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20010301)63:5 · Cited by 17
Cited by
Sorted by citations
Oxidative Stress: Harms and Benefits for Human Health
Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., Squadrito, F., Altavilla, D., & Bitto, A. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/8416763 · Cited by 4,837
Free Radicals, Antioxidants in Disease and Health
Department of Pharmacy, L. S. P. C. H., Pham-Huy, L. A., He, H., Department of Analytical Chemistry, C. P. U., Pham-Huyc, C., & Laboratory of Toxicology, F. O. P. (2008) · International Journal of Biomedical Science · doi:10.59566/ijbs.2008.4089 · Cited by 3,058
Halliwell, B., & Whiteman, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705776 · Cited by 2,238
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Biomarkers of Oxidative Damage in Human Disease
Dalle-Donne, I., Rossi, R., Colombo, R., Giustarini, D., & Milzani, A. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.061408 · Cited by 1,703
Metadata
- Authors
- Allan Butterfield, D.
- Venue
- Free Radical Research
- Publisher
- Informa UK Limited
- Published
- 2002-01
- Volume
- 36
- Issue
- 12
- Pages
- 1307-1313
- ISSN
- 1029-2470 (ISSN-L)
- 1071-5762
- OpenAlex
- W2153767421
- Cited by
- 786
- References
- 58
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 18 · 2023: 21 · 2022: 24 · 2021: 34 · 2020: 26 · 2019: 28 · 2018: 30 · 2017: 32 · 2016: 45 · 2015: 43 · 2014: 42 · 2013: 39 · 2012: 42
- FWCI
- 18.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Free Radical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Kentucky
- National Institute on Aging (P01AG010836, P01AG005119, AG 10836, AG12423, AG0 5119, R01AG012423)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid beta peptide 1-42, oxidative stress, neurotoxicity, Alzheimer's disease, protein oxidation, lipid peroxidation, nitrotyrosine, vitamin E, hippocampal neurons, synaptosomes, apolipoprotein E, APOE ε4, amyloid fibril formation, neurodegeneration, lipid bilayers
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Animals, Brain, Humans, Lipid Bilayers, Methionine, Molecular Sequence Data, Neurons, Peptide Fragments, Peptides, Free Radical Scavengers, Amyloid beta-Peptides, Reactive Oxygen Species, Protein Structure, Tertiary, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review